KALA BIO, Inc. — Investor Relations & Filings
KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on researching and developing innovative therapies for rare and severe eye diseases. The company utilizes its proprietary mesenchymal stem cell secretome (MSC-S) platform to create therapies with regenerative healing effects. Its lead product candidate, KPI-012, is a topical therapy in a Phase 2b clinical study for the treatment of persistent corneal epithelial defect (PCED), for which it has received Orphan Drug and Fast Track designations from the U.S. FDA. The pipeline also includes KPI-014, a preclinical, gene-agnostic intravitreal therapy being developed for inherited retinal degenerations. Following the sale of its commercial products in 2022, KALA BIO has concentrated its efforts on advancing its biologics pipeline for ophthalmic conditions.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q | 2026-05-15 | English | |
| 10-K - KALA BIO, Inc. (0001479419) (Filer) | 2026-04-15 | English | |
| D - KALA BIO, Inc. (0001479419) (Filer) | 2026-03-17 | English | |
| 144 - KALA BIO, Inc. (0001479419) (Subject) | 2026-03-17 | English | |
| 8-K - KALA BIO, INC. (0001479419) (Filer) | 2026-03-04 | English | |
| 8-K - KALA BIO, INC. (0001479419) (Filer) | 2026-02-20 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46361127 | 10-Q | 2026-05-15 | English | ||
| 34609902 | 10-K - KALA BIO, Inc. (0001479419) (Filer) | 2026-04-15 | English | ||
| 32967766 | D - KALA BIO, Inc. (0001479419) (Filer) | 2026-03-17 | English | ||
| 32967403 | 144 - KALA BIO, Inc. (0001479419) (Subject) | 2026-03-17 | English | ||
| 32892479 | 8-K - KALA BIO, INC. (0001479419) (Filer) | 2026-03-04 | English | ||
| 32892478 | 8-K - KALA BIO, INC. (0001479419) (Filer) | 2026-02-20 | English | ||
| 30041686 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 32892481 | S-3 - KALA BIO, INC. (0001479419) (Filer) | 2026-02-09 | English | ||
| 18339249 | 3 - KALA BIO, Inc. (0001479419) (Issuer) | 2026-02-09 | English | ||
| 18337689 | 3 - KALA BIO, Inc. (0001479419) (Issuer) | 2026-02-09 | English | ||
| 18331287 | 3 - KALA BIO, Inc. (0001479419) (Issuer) | 2026-02-09 | English | ||
| 18327819 | 3 - KALA BIO, Inc. (0001479419) (Issuer) | 2026-02-09 | English | ||
| 18326470 | 3 - KALA BIO, Inc. (0001479419) (Issuer) | 2026-02-09 | English | ||
| 30041682 | SCHEDULE 13D Filing | 2026-02-06 | English | ||
| 30041658 | 8-K Filing | 2026-02-05 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Aquestive Therapeutics, Inc.
Pharmaceutical company developing oral film medicines for C…
|
AQST | US | Manufacturing |
|
Arbutus Biopharma Corp
Clinical-stage biopharma company developing a functional cu…
|
ABUS | US | Manufacturing |
|
Arcellx, Inc.
A clinical-stage biotech company developing immunotherapies…
|
ACLX | US | Manufacturing |
|
Arctic Bioscience
Develops pharmaceutical and nutraceutical products from mar…
|
ABS | NO | Manufacturing |
|
ArcticZymes Technologies
Develops and manufactures novel recombinant enzymes from Ar…
|
AZT | NO | Manufacturing |
|
Arcturus Therapeutics Holdings Inc.
A commercial-stage mRNA medicines company focused on rare a…
|
ARCT | US | Manufacturing |
|
Arcus Biosciences, Inc.
A clinical-stage biopharmaceutical company developing combi…
|
RCUS | US | Manufacturing |
|
Arcutis Biotherapeutics, Inc.
Develops and commercializes treatments for immune-mediated …
|
ARQT | US | Manufacturing |
|
ARDELYX, INC.
Biopharmaceutical company developing medicines for cardiore…
|
ARDX | US | Manufacturing |
|
ARECOR THERAPEUTICS PLC
Biopharmaceutical company enhancing medicines with its prop…
|
AREC | GB | Manufacturing |
KALA BIO, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35091/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35091 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35091 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35091 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35091}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for KALA BIO, Inc. (id: 35091)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.